MIRA Pharmaceuticals, Inc. (MIRA) Revenue, Earnings & Financial Statements
$0.64NASDAQ: MIRAMarket Cap $26.89M
Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)
MIRA Pharmaceuticals, Inc. most recently reported annual revenue of $0, a net loss of $10.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
MIRA Pharmaceuticals, Inc.: net profit was positive in 0 of 6 reported years; the most recent year shows a net loss of $10.0M.
Income Statement — 6 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$0
Operating Expenses
$0
$2.0M
$7.0M
$9.0M
$8.0M
$10.0M
Operating Profit
$0
−$2.0M
−$7.0M
−$9.0M
−$8.0M
−$10.0M
Other Income
$0
$0
$0
−$3.0M
$0
$0
Interest
$0
$0
$0
$3.0M
$0
$0
Depreciation
$0
$2.0M
$7.0M
$0
$0
$0
Profit Before Tax
$0
−$2.0M
−$7.0M
−$12.0M
−$8.0M
−$10.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
$0
−$2.0M
−$7.0M
−$12.0M
−$8.0M
−$10.0M
EPS
$0.00
−$0.15
−$0.48
−$0.65
−$0.51
−$1.35
Quarterly Results — Last 12 Quarters (USD millions)
7 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$3.0M
$3.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$2.0M
$1.0M
$6.0M
$1.0M
$1.0M
Operating Profit
−$3.0M
−$3.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$1.0M
−$6.0M
−$1.0M
−$1.0M
Interest
$0
$3.0M
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$4.0M
−$6.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$1.0M
−$6.0M
−$1.0M
−$1.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$4.0M
−$6.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$2.0M
−$1.0M
−$6.0M
−$1.0M
−$1.0M
EPS
−$0.24
−$0.39
−$0.09
−$0.11
−$0.14
−$0.16
−$0.11
−$0.09
−$1.18
−$0.14
−$0.03
−$0.03
Over the 6 years reported for MIRA Pharmaceuticals, Inc., cash stood at $6.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 11.00 times.
Balance Sheet — 6 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
Total Assets
$0
$3.0M
$1.0M
$5.0M
$3.0M
$11.0M
Current Assets
$0
$3.0M
$0
$5.0M
$3.0M
$11.0M
Cash
$0
$3.0M
$0
$5.0M
$3.0M
$6.0M
Inventory
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$0
$0
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$0
$0
$0
Other Assets
$0
$0
$0
$0
$0
$0
Total Liabilities
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Current Liabilities
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Borrowings
$0
$0
$0
$0
$0
$0
Other Liabilities
$0
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Equity
$0
$0
$0
$0
$0
$0
Reserves
$0
$2.0M
−$1.0M
$4.0M
$2.0M
$10.0M
For MIRA Pharmaceuticals, Inc., operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was negative at $5.0M; free cash flow was positive in 0 of 6 years.
Cash Flow Statement — 6 Years (USD millions)
Metric
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$0
−$1.0M
−$6.0M
−$5.0M
−$6.0M
−$5.0M
Investing Cash Flow
$0
$0
$0
$0
$0
$0
Financing Cash Flow
$0
−$1.0M
$0
$0
$0
$0
Net Cash Flow
$0
$3.0M
−$2.0M
$4.0M
−$2.0M
$4.0M
Free Cash Flow
$0
−$1.0M
−$6.0M
−$5.0M
−$6.0M
−$5.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.00
EV / EBITDA
-2.06
FCF Yield
-20.13%
Quick Ratio
200.08
Interest Coverage
—
Return 1Y
-50.75%
Return 3Y
-61.40%
Return 5Y
—
MIRA Pharmaceuticals, Inc. (MIRA) financials — frequently asked questions
What is MIRA Pharmaceuticals, Inc.'s annual revenue?
MIRA Pharmaceuticals, Inc. (MIRA) reported annual revenue of $0 in its most recent fiscal year.
What is MIRA Pharmaceuticals, Inc.'s net profit?
MIRA Pharmaceuticals, Inc. (MIRA) reported a net loss of $10.0M in its most recent fiscal year.
What is MIRA EV/EBITDA?
MIRA Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -2.06. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Drug Manufacturers - General stocks